1.Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy.
Cook GC1. Parasitol Today. 1990 Apr;6(4):133-6.
The past two decades have seen some remarkable developments in anthelmintic chemotherapy in clinical medicine. Whereas praziquantel has revolutionized the management of many cestode and trematode infections, Gordon Cook explains how the introduction of the benzimidazoles - most importantly thiabendazole, mebendazole and recently albendazole (flubendazole, cambendazole, ciclobendazole, and triclabendazole have also been used on a very limited scale) - has had a major impact upon the safe and effective management of several important intestinal and systemic nematode and, to a leser extent, cestode infections.
2.Experimental chemotherapy of filariasis: comparative evaluation of the efficacy of filaricidal compounds in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi and B. pahangi.
Zahner H1, Schares G. Acta Trop. 1993 Jan;52(4):221-66.
Eleven types/classes of compound with antifilarial activity were comparatively evaluated in Mastomys coucha infected with Litomosoides carinii, Acanthocheilonema viteae, Brugia malayi or B. pahangi. The paper deals with the efficacy of (i) predominantly microfilaricidal compounds [diethylcarbamazine, levamisole, avermectins (ivermectin, milbemycin), nitrofurans (nitrofurantoin, hydroxymethylnitrofurantoin, nifurtimox, furazolidone, furapyrimidone), organophosphorals (metrifonate, haloxon), and aminophenyl-amidines], (ii) predominantly macrofilaricidal compounds [suramin, benzimidazoles (flubendazole, mebendazole, oxfendazole, ciclobendazole, albendazole, cambendazole, fenbendazole), and arsenicals (thiacetarsamide, Mel PH, R7/45)], and (iii) micro- and macrofilaricidal compounds [benzazole derivatives (CGP 20376 and other benzothiazoles) and nitrophenylamines (amoscanate, CGP 6140)]. Minimum effective doses against microfilariae and minimum curative doses against adult filariae as well as detailed data on dose-efficacy relationships are reported for the various drugs.
3.[Clinical evaluation of ciclobendazole (C-C 2481) in the treatment of colonic helminth diseases].
Degrémont A, Stahel E. Schweiz Med Wochenschr. 1978 Sep 16;108(37):1430-3.
A total of 105 patients with mild helminthiases have been treated with ciclobendazole, a benzimidazole derivative related to mebendazole. The treatment lasted 3 days. A group of 74 patients received 200 mg/day ciclobendazole while another 31 patients were given double this dose. The excretion rates achieved were very high at 84.2 and 83.3% respectively in trichuriasis and 93.3 and 100% respectively in ascariasis. In a relatively small number of cases of ankylostomiasis, the values were, however, considerable lower (38.5 and 20.0% respectively). Since ciclobendazole is well tolerated, there is a need for studies with higher dosages and possibly also long-term studies.
4.Comparative trial on the therapeutic effectiveness of the new anthelmintic drug: ciclobendazole.
Guggenmoos R, Akhtaruzzaman KM, Rosenkaimer F, Gaus W, Bienzle U, Dietrich M. Tropenmed Parasitol. 1978 Dec;29(4):423-6.
In a double-blind study in Cameroon the vermicidal effect of Ciclobendazole, a new Benzimidazole derivative, was evaluated and compared to Mebendazole. Ciclobendazole and Mebendazole were equally effective in the treatment of Ascaris and Hookworm infestations. An increase in the dosis of Ciclobendazole from 600 mg to 1200 mg did not lead to an improvement in the effectiveness. When treating trichuriasis significantly better results were achieved with Mebendazole (p = 0.01). Both drugs were tolerated equally well. Side effects, such as vomiting and diarrhoea, only occurred in a small percentage of cases.